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Extension of quality-by-design concept
to the early development phase of
pharmaceutical R&D processes
Ildikó Csóka, csoka@pharm.u-szeged.hu, Edina Pallagi and Tamás L. Paál
Here, we propose the extension of the quality-by-design (QbD) concept to also fit the early development
phases of pharmaceuticals by adding elements that are currently widely applied, but not yet included in
the QbD model in a structured way. These are the introduction of a ‘zero’ preformulation phase (i.e.,
selection of drug substance, possible dosage forms and administration routes based on the evaluated
therapeutic need); building in stakeholders’ (industry, patient, and regulatory) requirements into the
quality target product profile (QTTP); and the use of modern quality management tools during the
composition and process design phase [collecting critical quality attributes (CQAs) and selection of
CPPs) for (still laboratory-scale) design space (DS) development. Moreover, during industrial scale-up,
CQAs (as well as critical process parameters; CPPs) can be changed; however, we recommend that the
existing QbD elements are reconsidered and updated after this phase.
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QbD, as a quality management concept em-
phasizing the design of quality into products
and services, was introduced originally by Juran
[1]. After several years of use in different fields,
this concept reached the pharmaceutical sector,
concurrently with the improvement of quality
assurance methods used in pharmaceutical
manufacturing. It became clear that prior
knowledge of the stakeholders and their ex-
pectations of quality, together with the evalu-
ation of risks arising on the way to achieving the
targeted product, form a scientific knowledge-
based holistic and systematic way of pharma-
ceutical development [2]. The elements of the
QbD methodology are described in the ICH Q8
(R2) international guideline [3].1340 www.drugdiscoverytoday.comThe ‘minimum QbD approach’ presented in
the guideline comprises the definition of the
QTPP and the summary of the main product
characteristics, based on the stakeholders’ ex-
pectations. Moreover, it deals with the identifi-
cation and determination of the CQAs, followed
by the selection of the manufacturing process
and the definition of the in-process control
strategy. The definition of the CQAs is essential,
because they have the most influence on the
final product quality and performance charac-
teristics (affecting also safety and efficacy), and
need to be controlled.
By contrast, the enhanced QbD approach
shows more proactive step-by-step develop-
ment. It also comprises a risk assessment (RA)
and a DS development phase before the defi-nition of the control strategy. The philosophy of
continuous quality improvement manifests in
the presence of the lifecycle management and
continual improvement aspects involved in drug
discovery. Quality risk management and phar-
maceutical quality system approaches are
published in the relevant ICH guidelines (Q9 and
Q10) [4,5]. Application of the QbD approach in
marketing authorization procedures is both
preferred and highly recommended [6–8].
This QbD methodology, with the advantage of
promoting a better understanding of the ma-
terial characteristics and process parameters
affecting the final quality of the targeted
product, also brings a holistic and risk-based
structured way of thinking into industrial
manufacturing procedures.1359-6446/ã 2018 Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/j.drudis.2018.03.012
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largement with other, already existing tools for a
risk-based approach, the above QbD approach
could also be used to cover the early phases of
pharmaceutical research activities, resulting in
the time- and cost-effective transfer from the
research phase to market approval and indus-
trial-scale manufacturing. We summarize our
experiences of implementing the QbD approach
into different dosage form design processes (e.
g., [9–12]). In short, with only a partial extension
of the enhanced QbD approach described
above, an R&D QbD can be created.
Discussion
Figure 1 shows the enhanced QbD approach,
outlined above, complemented by us with the
new elements shown in red. These comprise a
preformulation (‘zero phase’) DS phase and the
‘a–d boxes’. The first two of these boxes are
detailed in Fig. 2.(6) Product 
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FIGURE 1
Proposal for a quality-by-design (QbD) flow chart adop
critical quality attributes; DoE, design of experimentsThe preformulation DS means the careful
assessment of the available biopharmaceutical
knowledge on the multidimensional elements
of ‘unmet therapeutic needs’ (in their broadest
meaning) as well as all the possibilities con-
cerning the administration route–dosage form–
drug substance triangle (the latter could be
synthetic, natural, or biological, inherently dif-
ferent e.g. in terms of their standardization and
variability). These initial steps can be labelled as
the ‘Zero design phase’ within the R&D process.
As a result of this phase, one can have a ‘space’
as a basis for the further points to be taken into
consideration to achieve the targeted quality
product. These interrelations and decisions in
this ‘0 phase’ are shown in Box (a) in Fig. 2.
This approach, complemented with a possible
benefit and risk assessment, has been success-
fully used previously. For example, Pallagi et al.
used this approach during the early develop-
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tration [9]. The approach also appeared to be
used successfully in the development of
meloxicam-containing dry powder for inhala-
tion comprising also a process map on the
production of a co-micronized (microcompo-
site) system and the creation of an Ishikawa
diagram collecting all the relevant influencing
factors. It helped also the authors in the selec-
tion of CQAs and the CPP [10]. The Ishikawa
diagram and Pareto charts also helped in CQA
and CPP selection during the early development
of a microparticle-based dry powder inhalation
formulation of ciprofloxacin hydrochloride [11].
Furthermore, Kovács et al. used this early QbD
approach successfully in the formulation de-
velopment of multiple emulsions for topical use
[12].
Box (b) in Figs. 1 and 2 illustrate the basic
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FIGURE 2
Interrelations, decisions in the zero phase (a) and the implementation of stakeholders’ expectations (b). Abbreviation: QTPP, Quality Target Product Profile.
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given product, depending on their field of in-
terest. Evaluation of these inputs forms the
second important part of this new R&D QbD
approach. The expanded way of defining the
target product profile comprises four aspects.
Based on prior knowledge, patient expectations,1342 www.drugdiscoverytoday.comsatisfaction, and adherence are interrelated
factors; therefore, all available patient aspects
experienced concerning a given therapy, ad-
ministration route, or dosage form should be fed
back into the development process. For in-
stance, combination products, as a rule, improve
patient adherence.Regulatory requirements and their imple-
mentation should be also taken into consider-
ation during the early phase of development; in
particular, the consequences of the type of the
submission are often neglected in the QbD
literature. Based on our experience, one should
evaluate the already marketed products in the
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type and concentration, dosage form, and so on,
to position the product in question properly and
choose among the submission types available
(e.g., new stand-alone submission); one should
also be aware of the limitations of the invention.
For a generic submission, the: CQAs of the
reference product should be strictly reproduced.
However, a well-positioned generic product may
also answer unmet therapeutic needs if placed
on a market where the originator does not exist.
(This explains why the introduction of certain
generics can result in a sudden increase in the
treated population and, consequently, the en-
vironmental exposure [13].)
In terms of the bibliographic or well-estab-
lished use submission, the relevance of the cited
bibliography to the CQAs of one’s product
should be verified, which is not always easy. For
example, in case of Biopharmaceutics Classifi-
cation System (BCS) II and IV drug substances, it
is difficult to prove that the product will be
similar to the marketed ones without perform-
ing comparative pharmacokinetic studies;
however, this is not needed if the drug sub-
stance belongs to BCS I or III class (i.e., dissolving
within the physiological pH range well).
Stakeholders from the manufacturing indus-
try focus on other aspects of quality and should
communicate their expectations, such as costs
of manufacturing, scale-up difficulties, and so
on. The fourth, relatively new aspect of devel-
oping new medicinal products is social re-
sponsibility; namely, favoring the different
‘green technologies and avoiding toxic and
hazardous materials during processing.
After this enlarged decoding of the QTPP,
determination of the quality attributes (QAs)
and the CQAs forms the next step, followed by
the selection of the (critical) material attributes
(MAs). These form an integral part of the com-
position and process design phase together
with the determination of the CPPs. The final
theoretical composition with a defined prepa-
ration methodology includes all the character-
istics defined by the above-mentioned four
aspects. To collect these influencing and relating
factors, several modern quality management
tools can be used, including Ishikawa diagrams
for evaluating cause–effect relations or the
setting up of a decision tree that helps the route
selection during the development process, as
well as Pareto analysis, which helps identify
causes of more frequent problems [10,11]. This is
the third ‘expansion’ of the classical QbD
method, and it is indicated by Box (c) in Fig. 1.Last but not least, the following modification of
the classical QbD flow chart is recommended to
be performed after the DS development phase.
Generally, the DS is determined by applying dif-
ferent factorial design possibilities and the factors
identified as being critical are then used in the
given formulation development. It is the multi-
dimensional combinationand interactionof input
variables (e.g., material attributes) and process
parameters that have been demonstrated to
provide an assurance of quality [3,14–17] (i.e., the
‘space’ where CQAs are met given variations in
CPPs within a well-defined domain). This is de-
termined both on a laboratory scale and in the
manufacturing environment. However, CPPs (and
sometimes MAs) often, and almost inevitably,
change during scale-up and/or during the real
manufacturing environment. Thus, we recom-
mended reconsidering and updating the existing
QbD plan after this phase. This is the fourth
expansion and indicated by Box (d) in Fig. 2.
(Naturally, reconsideration of CQAs and CPPs form
part of the product lifecycle management and
continuous improvement stages, which are in-
tegral to the QbD approach. However, our ex-
perience suggests that the biggest changes in
these parameters are expected during scale-up
from laboratory to pilot manufacturing scale. This
is emphasized in our proposed extension.)
The additional steps provided in Fig. 1 (5 and
6) remain unchanged.
Concluding remarks
The early (laboratory-scale) development phase
of pharmaceuticals, where the QbD approach
should be followed, comprises elements that are
currently missing from the existing QbD model
[6–8]. Introduction of necessary (probably al-
ready widely used) elements into the enhanced
QbD model could create an R&D QbD that is
more suitable for the early development phase
of pharmaceutical formulations. Such elements
comprise the assessment of unmet therapeutic
needs, the choice of drug substance type in
correlation with the administration route and
dosage form (preformulation study design),
building in stakeholder expectations, use of
modern risk assessment tools during the ex-
perimental (composition) design, then reconsi-
dering and updating as required the resulting
(laboratory) DS after manufacturing scale-up.
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